Page 22 – AAKP

FDA and CMS Decisions are Key to Increased Transplantation for Highly-HLA Sensitized Kidney Patients

January 14, 2021

By Lana Schmidt, MBA, former home hemodialysis patient, current transplant recipient, AAKP National Board of Director As an 18-year kidney patient warrior, I know firsthand what it is like to have too many antibodies and a very low chance, if ever, of receiving a kidney transplant.

January 7, 2021

By Seema Verma, Administrator of the Centers for Medicare and Medicaid Services (CMS) Today, more than 100,000 Americans are on waiting lists to receive a lifesaving organ transplant. A new name is added to the national transplant waiting list every 10 minutes.

January 6, 2021

By Paul T. Conway AAKP Chair of Policy & Government Affairs Editor’s Note: Mr. Conway, a 40-year kidney patient and 23-year transplant recipient, has worked in support of five U.S. presidential transitions. He leads AAKP efforts related to the Trump/Biden Presidential Transition.

Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

December 30, 2020

ERA-EDTA Council and the ERACODA Working Group* Correspondence to: Alberto Ortiz, E-mail: AOrtiz@fjd.es*A list of members of the ERA-EDTA Council and the ERACODA Working Group can be found as Acknowledgements section.

December 27, 2020

Transplant Drug Reform A Milestone in First Year of AAKP’s Decade of the Kidney Washington, D.C.: The American Association of Kidney Patients (AAKP), the largest and oldest kidney patient organization in the United States, released the following statement upon President Donald J.

December 21, 2020

FOR IMMEDIATE RELEASE: December 21, 2020 MEDIA CONTACTS: Jennifer Duplessie, Marketing and Communications Manager jduplessie@aakp.org (512) 659-8818 Diana Clynes, Executive Director dclynes@aakp.org (727) 916-0390 KIDNEY PATIENTS HAIL U.S.

December 16, 2020

December 16, 2020 Nikolay P. Nikolov, MDDirector, Division of Rheumatology and Transplant MedicineFood and Drug AdministrationCenter for Drug Evaluation and ResearchDivision of Rheumatology and Transplant Medicine5901-B Ammendale RoadBeltsville, MD 20705-1266Re:

Kidney Patients Making National Impact Helping Patients During National Pandemic

December 11, 2020

World Kidney News/Urban Health Outreach Media hosted a special broadcast featuring the executive leadership of the American Association of Kidney Patients: Diana Clynes, Executive Director; Richard Knight, President; Edward V. Hickey, III, U.S.M.C., Vice President, Chair of AAKP Veterans Health Initiative; and Paul T.

TOP KIDNEY GROUP SALUTES CONGRESSIONAL ACTION ON TRANSPLANT DRUGS FOR PATIENTS

December 9, 2020

FOR IMMEDIATE RELEASE: December 9, 2020 TOP KIDNEY GROUP SALUTES CONGRESSIONAL ACTION ON TRANSPLANT DRUGS FOR PATIENTS AAKP Calls for Immediate Senate Action, Asks President Trump to Sign Upon Passage Washington, D.C.: The American Association of Kidney Patients (AAKP) released the following statement regarding the U.S.

December 8, 2020

You are very well known across the larger kidney community for leadership, medical expertise and respect for patient insights. For AAKP readers, can you tell us how patients have informed your view of medicine, and your role as a thought leader in kidney medicine and kidney innovation?

FDA and CMS Decisions are Key to Increased Transplantation for Highly-HLA Sensitized Kidney Patients

Organ Procurement Organizations

American Presidential Transitions – AAKP’s Strategic and Ongoing Role

Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA

LARGEST KIDNEY GROUP THANKS PRESIDENT TRUMP FOR SIGNING PANDEMIC RELIEF AND TRANSPLANT DRUG COVERAGE

KIDNEY PATIENTS HAIL U.S. SENATE MOVE ON TRANSPLANT DRUGS

December 16, 2020: AAKP & AST joint letter to FDA on importance of supporting rational clinical trial design and support for kidney transplant desensitization

Kidney Patients Making National Impact Helping Patients During National Pandemic

TOP KIDNEY GROUP SALUTES CONGRESSIONAL ACTION ON TRANSPLANT DRUGS FOR PATIENTS

Innovator Series: Q&A with Dr. Ray Harris